Proteolysis
Nurix Therapeutics Announces Closing of Underwritten Registered Offering
Nurix Therapeutics, a clinical-stage biopharmaceutical company, has announced the successful completion of its underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share, generating gross proceeds of $250.0 million. The company plans to use the net proceeds from